Vivaldis AtovaQuin-250 is a potent veterinary-grade antiprotozoal medication used in the treatment of critical protozoal infections in both dogs and cats. Each uncoated tablet contains Atovaquone USP 250 mg, known for its efficacy against organisms such as Babesia gibsoni, Cytauxzoon felis, and Pneumocystis canis. Administered in combination with azithromycin, AtovaQuin-250 offers a targeted approach to managing severe and life-threatening infections associated with tick-borne and respiratory protozoal pathogens.
Formulated by Vivaldis Animal Health, a leader in advanced veterinary therapeutics, this medication reflects cutting-edge innovation in companion animal care, ensuring faster recovery and better clinical outcomes.
Recommended and trusted by veterinarians, AtovaQuin-250 is an essential inclusion in the treatment protocol for protozoal conditions requiring aggressive management.
Composition
Indications
Dosage & Administration
To be given orally in combination with Azithromycin, for 10 consecutive days, or as directed by the veterinarian:
Benefits
-
Effective against multiple protozoal organisms causing serious systemic infections
-
Highly bioavailable formulation for improved absorption and efficacy
-
Supports faster recovery when used alongside azithromycin
-
Designed specifically for veterinary use in dogs and cats
-
A valuable therapeutic option in managing resistant or recurring tick-borne illnesses
Other Details
-
Pack Size: 1 Strip of 10 Tablets
-
Presentation: Mono carton
-
Route: Oral
-
Form: Uncoated tablets
-
Use: For veterinary use only
-
Manufacturer: Vivaldis Animal Health
Brand Insight
AtovaQuin-250 is brought to you by Vivaldis Animal Health, known for its commitment to excellence in companion animal treatment through evidence-based, novel therapeutic options.
Available now at PᴇᴛsLɪғᴇsᴛʏʟᴇ – curated with veterinary expertise by Vɪsʜɴᴜ Dᴜᴛᴛ Tʀɪᴘᴀᴛʜɪ | Pᴇᴛ Exᴘᴇʀᴛ.
For queries or guidance on dosage, consult your veterinarian or contact us directly.
